NasdaqGM:SCYX

Stock Analysis Report

Executive Summary

SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States.

Rewards

Loading interface...

Risk Analysis

Loading interface...

Snowflake Analysis

Limited growth with imperfect balance sheet.

Share Price & News

How has SCYNEXIS's share price performed over time and what events caused price changes?


Latest Share Price and Events

Information is not available.


Market Performance


7 Day Return

-22.7%

SCYX

2.1%

US Pharmaceuticals

1.3%

US Market


1 Year Return

51.4%

SCYX

1.0%

US Pharmaceuticals

19.4%

US Market

Information is not available.

Information is not available.


Shareholder returns

SCYXIndustryMarket
7 Day-22.7%2.1%1.3%
30 Day-37.1%6.9%2.6%
90 Day-32.5%9.2%5.0%
1 Year51.4%51.4%3.7%1.0%22.0%19.4%
3 Year-77.2%-77.2%30.4%21.0%46.8%37.3%
5 Year-92.9%-92.9%24.5%11.3%66.3%48.0%

Price Volatility Vs. Market

How volatile is SCYNEXIS's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is SCYNEXIS undervalued compared to its fair value and its price relative to the market?

6.93x

Price to Book (PB) ratio


Share Price vs. Fair Value

Information is not available.

Information is not available.


Price To Earnings Ratio

Information is not available.

Information is not available.


Price to Earnings Growth Ratio

Information is not available.


Price to Book Ratio

Information is not available.


Next Steps

Future Growth

How is SCYNEXIS forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

31.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Information is not available.

Information is not available.

Information is not available.

Information is not available.

Information is not available.


Earnings per Share Growth Forecasts


Future Return on Equity

Information is not available.


Next Steps

Past Performance

How has SCYNEXIS performed over the past 5 years?

-3.9%

Historical annual earnings growth


Earnings and Revenue History

Information is not available.

Information is not available.


Past Earnings Growth Analysis

Information is not available.

Information is not available.

Information is not available.


Return on Equity

Information is not available.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is SCYNEXIS's financial position?


Financial Position Analysis

Information is not available.

Information is not available.


Debt to Equity History and Analysis

Information is not available.

Information is not available.

Information is not available.

Information is not available.


Balance Sheet

Information is not available.

Information is not available.


Next Steps

Dividend

What is SCYNEXIS's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.7%forecastin3Yearsn/a

Current dividend yield vs market & industry

Information is not available.

Information is not available.


Stability and Growth of Payments

Information is not available.

Information is not available.


Current Payout to Shareholders

Information is not available.


Future Payout to Shareholders

Information is not available.


Next Steps

Management

What is the CEO of SCYNEXIS's salary, the management and board of directors tenure and is there insider trading?

4.3yrs

Average management tenure


CEO

Marco Taglietti (59yo)

4.7yrs

Tenure

US$1,114,895

Compensation

Dr. Marco Taglietti, M.D. has been the Chief Executive Officer of SCYNEXIS, Inc. since April 1, 2015 and has been President since September 24, 2015. Dr. Taglietti served as Senior Vice President, Head of  ...


CEO Compensation Analysis

Information is not available.

Information is not available.


Management Age and Tenure

4.3yrs

Average Tenure

49yo

Average Age

Information is not available.


Board Age and Tenure

4.7yrs

Average Tenure

60.5yo

Average Age

Information is not available.


Insider Trading

Information is not available.


Recent Insider Transactions

BuyUS$11,10022 Aug 19
Marco Taglietti
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares10,000
Max PriceUS$1.11
BuyUS$10,11519 Aug 19
Marco Taglietti
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares10,015
Max PriceUS$1.01
BuyUS$40,75018 Apr 19
Marco Taglietti
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares25,000
Max PriceUS$1.63
BuyUS$17,25014 Jan 19
Marco Taglietti
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares25,000
Max PriceUS$0.69
BuyUS$11,50002 Jan 19
Marco Taglietti
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares25,000
Max PriceUS$0.46
BuyUS$5,95102 Jan 19
David Angulo
EntityIndividual
Role
Senior Key Executive
Chief Medical Officer
Shares12,000
Max PriceUS$0.50

Ownership Breakdown

Information is not available.


Management Team

  • Marco Taglietti (59yo)

    CEO, President & Director

    • Tenure: 4.7yrs
    • Compensation: US$1.11m
  • David Angulo (54yo)

    Chief Medical Officer

    • Tenure: 4.5yrs
    • Compensation: US$768.61k
  • Eric Francois (44yo)

    Chief Financial Officer

    • Tenure: 4.1yrs
    • Compensation: US$664.70k
  • Scott Sukenick (41yo)

    General Counsel & Corporate Secretary

    • Tenure: 2.1yrs

Board Members

  • Armando Anido (61yo)

    Independent Director

    • Tenure: 0.9yrs
  • Dave Hastings (58yo)

    Independent Director

    • Tenure: 4.3yrs
    • Compensation: US$72.75k
  • Ann Hanham (66yo)

    Independent Director

    • Tenure: 11yrs
    • Compensation: US$72.75k
  • Guy MacDonald (60yo)

    Independent Chairman of the Board

    • Tenure: 4.5yrs
    • Compensation: US$81.83k
  • Steve Gilman (66yo)

    Independent Director

    • Tenure: 4.8yrs
    • Compensation: US$69.00k
  • David Denning

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Marco Taglietti (59yo)

    CEO, President & Director

    • Tenure: 4.7yrs
    • Compensation: US$1.11m
  • Peter Pappas

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Oliver Cornely

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Barbara Alexander

    Member of Scientific Advisory Board

    • Tenure: 0yrs

Company Information

SCYNEXIS, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: SCYNEXIS, Inc.
  • Ticker: SCYX
  • Exchange: NasdaqGM
  • Founded: 1999
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$72.167m
  • Shares outstanding: 97.26m
  • Website: https://www.scynexis.com

Number of Employees


Location

  • SCYNEXIS, Inc.
  • 1 Evertrust Plaza
  • 13th Floor
  • Jersey City
  • New Jersey
  • 7302
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SCYXNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDMay 2014
135DB (Deutsche Boerse AG)YesCommon StockDEEURMay 2014
0L49LSE (London Stock Exchange)YesCommon StockGBUSDMay 2014

Biography

SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intrave ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/13 00:15
End of Day Share Price2019/12/12 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.